Who are Opsumit's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Letairis, Tracleer, Azo Gantrisin, Gantrisin, Pivlaz, Ambrisentan plus Spironolactone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/macitentan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Opsumit — Competitive Intelligence Brief

Opsumit (MACITENTAN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Endothelin Receptor Antagonist [EPC]. Area: Metabolic.

marketed Endothelin Receptor Antagonist [EPC] Endothelin-1 receptor Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Opsumit (MACITENTAN) — AstraZeneca. Opsumit works by blocking the action of endothelin-1, a protein that causes blood vessels to constrict and increase blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Opsumit TARGET	MACITENTAN	AstraZeneca	marketed	Endothelin Receptor Antagonist [EPC]	Endothelin-1 receptor	2013-01-01
Letairis	AMBRISENTAN	Gilead Sciences	marketed	Endothelin Receptor Antagonist [EPC]	Endothelin-1 receptor	2007-01-01
Tracleer	BOSENTAN	AstraZeneca	marketed	Endothelin Receptor Antagonist	Endothelin-1 receptor	2001-01-01
Azo Gantrisin	sulfafurazole	Alra	marketed	Sulfonamide Antimicrobial	Endothelin-1 receptor	1971-01-01
Gantrisin	SULFISOXAZOLE ACETYL	Roche	marketed		Endothelin B receptor, Endothelin-1 receptor, Dihydropteroate synthase	1953-01-01
Pivlaz	CLAZOSENTAN	Idorsia Pharmaceuticals Japan Ltd	marketed		Endothelin-1 receptor
Ambrisentan plus Spironolactone	Ambrisentan plus Spironolactone	Brigham and Women's Hospital	marketed	Endothelin receptor antagonist + Mineralocorticoid receptor antagonist combination	Endothelin-1 receptor (ETA/ETB) + Mineralocorticoid receptor

Recent regulatory actions (last 90 days)

2026-03-03 — Tracleer · FDA · approved · US · AstraZeneca

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-05-15 — Tracleer · 8309126 · Formulation · US
2027-12-28 — Tracleer · 7959945 · Formulation · US

Sponsor landscape (Endothelin Receptor Antagonist [EPC] class)

· 1 drug in this class
AstraZeneca · 1 drug in this class
Gilead Sciences · 1 drug in this class
Idorsia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Opsumit — Competitive Intelligence Brief. https://druglandscape.com/ci/macitentan. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab